Bibliografía del artículo
1. Valentine C, Deenmamode J, Sherwood R. Didanosine and amylase monitoring. Lancet 1992; 339:999.
2. Foisy MM, Slayter KL, Hewitt RG, Morse GD. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother 1994; 28:1025-1028.
3. Murphy RL, Noskin GA, Ehrenpreis ED. Acute pancreatitis associated with pentamidine with aerosol. Am J Med 1990; 88:53-55.
4. Lankisch PG, Dröge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut 1995; 37:565-567.
5. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med 1999; 107:78-84.
6. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001; 15:617-620.
7. Guo JJ, Jang R, Louder A, Cluxton RJ. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus. Pharmacotherapy 2005; 25:1044-1054.
8. Haugaard SB, Andersen O, Dela F, et al. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 2005; 152:103-112.
9. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22:54-59.
10. Menges M, Pees HW. Kaposi's sarcoma of the pancreas mimicking pancreatic cancer in an HIV-infected patient. Clinical diagnosis by detection of HHV 8 in bile and complete remission following antiviral and cytostatic therapy with paclitaxel. Int J Pancreatol 1999; 26:193-199.
11. Barthet M, Chauveau E, Bonnet E, et al. Pancreatic ductal changes in HIV-infected patients. Gastrointest Endosc 1997; 45:59-63.
12. Laguno M, Milinkovic A, De Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10:423-429.
13. Manfredi R. HIV infection and advanced age: emerging epidemiological, clinical, and management issues. Ageing Res Rev 2004; 3:31-54.
14. Zazzo JF, Pichon F, Regnier B. HIV and the pancreas. Lancet 1987; ii:1212-1213.
15. Lambertus MW, Anderson RE. Hyperamilasemia in patients with human immunodeficiency virus infection. N Engl J Med 1990; 323:1708-1709.
16. Pezzilli R, Gullo L, Ricchi E, et al. Serum pancreatic enzymes in HIV-seropositive patients. Dig Dis Sci 1992; 37:286-288.
17. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992; 87:708-713.
18. Brivet FG, Naveau SH, Lemaigre GF, Dormont J. Pancreatic lesions in HIV-infected patients. Ball Clin Endrocrinol Metab 1994; 8:859-877.
19. Cappell MS, Marks M. Acute pancreatitis in HIV-seropositive patients: a case-control study of 44 patients. Am J Med 1995; 98:243-248.
20. Boix V, Portilla J, Merino E, Pérez-Mateo M. Origin of hyperamilasemia in HIV-infected patients. AIDS 1996; 10:553-555.
21. Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol 1997; 92:2044-2048.
22. Dowell SF, Holt EA, Murphy FK. Pancreatitis associated with human immunodeficiency virus infection: a matched case-control study. Tex Med 1996; 92:44-49.
23. Miller FH, Gore RM, Nemcek AA Jr, Fitzgerald SW. Pancreaticobiliary manifestations of AIDS. Am J Roentgenol 1996; 166:1269-1274.
24. Chehter EZ, Longo MA, Laudanna AA, Duarte ML. Involvemement of the pancreas in AIDS: a prospective study of 109 post-mortems. AIDS 2000; 14:1879-1886.
25. Foo Y, Konecny P. Hyperamylasemia in asymptomatic HIV patients. Ann Clin Biochem 1997; 34:259-262.
26. Argiris A, Mathur-Wagh U, Wilets I, Mildvan D. Abnormalities of serum amylase and lipase in HIV-positive patients. Am J Gastroenterol 1999; 94:1248-1252.
27. Carroccio A, Fontana M, Spagnolo MI, et al. Serum pancreatic enzymes in human immunodeficiency virus-infected children. Scand J Gastroenterol 1998; 33:998-1001.
28. Rondanelli M, Caselli D, Trotti R, et al. Endocrine pancreatic dysfunction in HIV-infected children: association with growth alterations. J Infect Dis 2004; 190:908-912.
29. Bitnun A, Sochett E, Dick PT, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90:168-174.
30. Hancock MR, Smith NA, Hawkins DA, Gazzard B, Ball SG. Biochemical assessment of pancreatic disease in human immunodeficiency virus infected men. J Clin Pathol 1997; 50:674-676.
31. Eleccion CB, Hathaway AA. Macroamylasemia in HIV infection. Tex Med 1998; 94:77-79.
32. Carroccio A, Di Prima L, Di Grigoli C, et al. Exocrine pancreatic function and fat malabsorption in human immunodeficiency virus-infected patients. Scand J Gastroenterol 1999; 34:729-734.
33. Sentongo TA, Rutstein RM, Stettler N, Stallings VA, Rudy B, Mulberg AE. Association between steatorrhea, growth, and immunologic status in children with perinatally acquired HIV infection. Arch Pediatr Adolescent Med 2001; 155:149-153.
34. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001; 42:181-188.
35. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21:209-216.
36. Verucchi G, Calza L, Biagetti C, Attard L, Costigliola P, Manfredi R. Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35:326-328.
37. Baril L, Beucler I, Valantin MA, et al. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 2001; 16:415-417.
38. Banks PA. Practice guidelines in acute pancreatitis. Am J Gastroenterol 1997; 92:377-386.
39. Goecke H, Forssmann U, Uguccioni M, et al. Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR 5. Surgery 2000; 128:806-814.
40. Kysia RF, Brown DF, Nadel ES. Abdominal pain in a patient with HIV. J Emerg Med 2004; 27:285-289.
41. Pezzilli R, Miglioli M. Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Dig Liver Dis 2001; 33:49-57.
42. Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Alimen Pharmacol Ther 1998; 12:237-245.
43. Bradley EL. Gabexate mesilate in acute pancreatitis: miracle or mirage? Dig Liver Dis 2001; 33:12-13.
44. Manfredi R, Vezzadini P, Costigliola P, Ricchi E, Fanti MP, Chiodo F. Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide. AIDS 1993; 7:223-226.
45. Manfredi R, Vezzadini P, Fanti MP, Chiodo F. Vasoactive intestinal polipeptide (VIP) secretion and refractory diarrea in patients with AIDS or AIDS-related complex (ARC). Scand J Infect Dis 1994; 26:55-57.
46. Vidal J, Sacanella E, Muñoz E, Miro JM, Navarro S. Acute pancreatitis related to octreotide in a patient with acquired immunodeficiency syndrome. Pancreas 1994; 9:395-397.